Showing results (101-110 of 119) with videos related to

Sort By:
Pageof 12
Leukemia|December 1, 1996
Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 studyJ Reiffers, A M Stoppa, M Attal, et al.
Journal of Hematotherapy|December 1, 1996
Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: the number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recoveryC Faucher, A G Le Corroller, C Chabannon, et al.
Leukemia & Lymphoma|December 30, 1998
A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemiaD Maraninchi, N Vey, P Viens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2000
Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patientsN Milpied, B Vasseur, N Parquet, et al.
Leukemia|March 1, 1996
A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75J Reiffers, F Huguet, A M Stoppa, et al.
Leukemia|August 15, 2000
Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL groupP Fenaux, S Chevret, A Guerci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Therapy-related acute promyelocytic leukemiaM Beaumont, M Sanz, P M Carli, et al.
Leukemia|August 10, 2012
Minor clone provides a reservoir for relapse in multiple myelomaF Magrangeas, H Avet-Loiseau, W Gouraud, et al.
Leukemia|May 13, 2005
Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL GroupC Callens, S Chevret, J-M Cayuela, et al.
Leukemia|August 18, 1999
Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial)X Thomas, P Fenaux, H Dombret, et al.
Pageof 12